Loading clinical trials...

UNKNOWNNA

Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer

Prospective Evaluation of Hypofractionated Stereotactic RT (SBRT) Using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer.

NCT03225235•The Greater Poland Cancer Centre

View on ClinicalTrials.gov

Summary

The main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients with low and intermediate risk of progression prostate cancer.

Detailed Description

Evaluation of the usefulness expression of selected proteins (PTEN, SMAD4, Cyclin D1, SPP1) as prognostic and predictive factors.

Eligibility

Age

40 - 75 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•men from 40 to 75 years of age with a confirmed adenocarcinoma prostate, prostate biopsy will be performed \<180 days prior to the randomization date,
•completed assessment of tumor differentiation according to Gleason grading allows to perform stratification;
•general Performance Status according to the Eastern Cooperative Oncology Group (ECOG) classification ( 0 -1),
•belonging to the group of low and intermedium risk of progression; (cT1-cT2c, Gleason 7, PSA to 19.9 ng / ml), cT specified by AJCC 7 Edition (appendix 2),
•PSA marked at least 10 days after or before the biopsy, and for patients taking phytosterol 30 days after discontinuation,
•no distant metastases,
•signing informed consent,
•morphological and biochemical blood parameters within the normal limits.

Exclusion Criteria

•the presence of active cancer, except skin cancer preceding period 5 years prior to randomization,
•surgical treatment (radical prostatectomy) or RT in the pelvic area,
•co-morbidities that may significantly affect the expectancy life of the patients
•do not meet the criteria for inclusion.

Locations (1)

Greater Poland Cancer Centre

Poznan, Wielkopolska, Poland

Key Dates

Start Date

August 26, 2013

Primary Completion Date

December 1, 2020

Completion Date

August 1, 2025

Last Updated

February 5, 2020

Enrollment

600

ESTIMATED participants

Conditions

Prostate Cancer

Interventions

SBRT

RADIATION

Contacts

Piotr Milecki, PhD., MD

CONTACT

+48618850878 piotr.milecki@wco.pl

Sylwia Krąkowska, MD

CONTACT

+48 61 885 08 78 sylwia.krakowska@wco.pl

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498

Metastatic Castration-Resistant Prostate Cancer

View study

RECRUITINGPHASE2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer

Inclusion Criteria

Exclusion Criteria

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC